Patents by Inventor Kenneth W. Dobie

Kenneth W. Dobie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of MARK3 expression
    Publication number: 20030232771
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MARK3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MARK3. Methods of using these compounds for modulation of MARK3 expression and for treatment of diseases associated with expression of MARK3 are provided.
    Type: Application
    Filed: June 17, 2002
    Publication date: December 18, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of amyloid beta protein precursor expression
    Publication number: 20030232435
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of amyloid beta protein precursor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding amyloid beta protein precursor. Methods of using these compounds for modulation of amyloid beta protein precursor expression and for treatment of diseases associated with expression of amyloid beta protein precursor are provided.
    Type: Application
    Filed: June 14, 2002
    Publication date: December 18, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Kenneth W. Dobie
  • Antisense modulation of PTPN12 expression
    Publication number: 20030232434
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTPN12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN12. Methods of using these compounds for modulation of PTPN12 expression and for treatment of diseases associated with expression of PTPN12 are provided.
    Type: Application
    Filed: June 17, 2002
    Publication date: December 18, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Lex M. Cowsert, Kenneth W. Dobie
  • Antisense modulation of extracellular-signal-regulated kinase-6 expression
    Publication number: 20030232772
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of extracellular-signal-regulated kinase-6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding extracellular-signal-regulated kinase-6. Methods of using these compounds for modulation of extracellular-signal-regulated kinase-6 expression and for treatment of diseases associated with expression of extracellular-signal-regulated kinase-6 are provided.
    Type: Application
    Filed: June 17, 2002
    Publication date: December 18, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie
  • Antisense modulation of DRAK1 expression
    Publication number: 20030232773
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of DRAK1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding DRAK1. Methods of using these compounds for modulation of DRAK1 expression and for treatment of diseases associated with expression of DRAK1 are provided.
    Type: Application
    Filed: June 17, 2002
    Publication date: December 18, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of VEGF-B expression
    Publication number: 20030232439
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of VEGF-B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding VEGF-B. Methods of using these compounds for modulation of VEGF-B expression and for treatment of diseases associated with expression of VEGF-B are provided.
    Type: Application
    Filed: June 17, 2002
    Publication date: December 18, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Hong Zhang, Kenneth W. Dobie
  • Extracellular-signal-regulated kinase-6 inhibitors for inhibiting angiogenesis
    Publication number: 20030232778
    Abstract: Compounds, compositions and methods are provided for modulating the expression of extracellular-signal-regulated kinase-6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding extracellular-signal-regulated kinase-6. Methods of using these compounds for modulation of extracellular-signal-regulated kinase-6 expression and for diagnosis and treatment of disease associated with expression extracellular-signal-regulated kinase-6 are provided.
    Type: Application
    Filed: January 17, 2003
    Publication date: December 18, 2003
    Inventors: Eric G. Marcusson, C. Frank Bennett, Kenneth W. Dobie
  • Antisense modulation of dual specific phosphatase 4 expression
    Publication number: 20030232441
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of dual specific phosphatase 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding dual specific phosphatase 4. Methods of using these compounds for modulation of dual specific phosphatase 4 expression and for treatment of diseases associated with expression of dual specific phosphatase 4 are provided.
    Type: Application
    Filed: June 17, 2002
    Publication date: December 18, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, C. Frank Bennett, Kenneth W. Dobie
  • Antisense modulation of KOX 1 expression
    Publication number: 20030232438
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of KOX 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding KOX 1. Methods of using these compounds for modulation of KOX 1 expression and for treatment of diseases associated with expression of KOX 1 are provided.
    Type: Application
    Filed: June 17, 2002
    Publication date: December 18, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Kenneth W. Dobie, Susan M. Freier
  • Antisense modulation of isoprenylcysteine carboxyl methyltransferase expression
    Publication number: 20030228688
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of isoprenylcysteine carboxyl methyltransferase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding isoprenylcysteine carboxyl methyltransferase. Methods of using these compounds for modulation of isoprenylcysteine carboxyl methyltransferase expression and for treatment of diseases associated with expression of isoprenylcysteine carboxyl methyltransferase are provided.
    Type: Application
    Filed: May 31, 2002
    Publication date: December 11, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Kenneth W. Dobie
  • Antisense modulation of IL-1 receptor-associated kinase-1 expression
    Publication number: 20030228690
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of IL-1 receptor-associated kinase-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding IL-1 receptor-associated kinase-1. Methods of using these compounds for modulation of IL-1 receptor-associated kinase-1 expression and for treatment of diseases associated with expression of IL-1 receptor-associated kinase-1 are provided.
    Type: Application
    Filed: June 10, 2002
    Publication date: December 11, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brenda F. Baker, Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of G protein-coupled receptor kinase 6 expression
    Publication number: 20030228689
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor kinase 6. Methods of using these compounds for modulation of G protein-coupled receptor kinase 6 expression and for treatment of diseases associated with expression of G protein-coupled receptor kinase 6 are provided.
    Type: Application
    Filed: May 31, 2002
    Publication date: December 11, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of beta-site APP-cleaving enzyme 2 expression
    Publication number: 20030224517
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of beta-site APP-cleaving enzyme 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding beta-site APP-cleaving enzyme 2. Methods of using these compounds for modulation of beta-site APP-cleaving enzyme 2 expression and for treatment of diseases associated with expression of beta-site APP-cleaving enzyme 2 are provided.
    Type: Application
    Filed: June 4, 2002
    Publication date: December 4, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Kenneth W. Dobie
  • Antisense modulation of sterol regulatory element-binding protein-1 expression
    Publication number: 20030224515
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of sterol regulatory element-binding protein-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding sterol regulatory element-binding protein-1. Methods of using these compounds for modulation of sterol regulatory element-binding protein-1 expression and for treatment of diseases associated with expression of sterol regulatory element-binding protein-1 are provided.
    Type: Application
    Filed: June 4, 2002
    Publication date: December 4, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Susan M. Freier, Brenda F. Baker, Kenneth W. Dobie
  • Antisense modulation of Notch1 expression
    Publication number: 20030224513
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Notch1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Notch1. Methods of using these compounds for modulation of Notch1 expression and for treatment of diseases associated with expression of Notch1 are provided.
    Type: Application
    Filed: May 30, 2002
    Publication date: December 4, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Susan M. Freier, Kenneth W. Dobie, Erich Koller
  • Antisense modulation of prox-1 expression
    Publication number: 20030224516
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of prox-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding prox-1. Methods of using these compounds for modulation of prox-1 expression and for treatment of diseases associated with expression of prox-1 are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: December 4, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Kenneth W. Dobie
  • Antisense modulation of beta-site APP-cleaving enzyme expression
    Publication number: 20030224512
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of beta-site APP-cleaving enzyme. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding beta-site APP-cleaving enzyme. Methods of using these compounds for modulation of beta-site APP-cleaving enzyme expression and for treatment of diseases associated with expression of beta-site APP-cleaving enzyme are provided.
    Type: Application
    Filed: May 31, 2002
    Publication date: December 4, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Kenneth W. Dobie
  • Antisense modulation of cathepsin Z expression
    Publication number: 20030224511
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cathepsin Z. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cathepsin Z. Methods of using these compounds for modulation of cathepsin Z expression and for treatment of diseases associated with expression of cathepsin Z are provided.
    Type: Application
    Filed: May 31, 2002
    Publication date: December 4, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Kenneth W. Dobie
  • Antisense modulation of phosphoinositide-3-kinase, regulatory subunit 4, p150 expression
    Publication number: 20030225013
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of phosphoinositide-3-kinase, regulatory subunit 4, p150. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phosphoinositide-3-kinase, regulatory subunit 4, p150. Methods of using these compounds for modulation of phosphoinositide-3-kinase, regulatory subunit 4, p150 expression and for treatment of diseases associated with expression of phosphoinositide-3-kinase, regulatory subunit 4, p150 are provided.
    Type: Application
    Filed: May 31, 2002
    Publication date: December 4, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Susan M. Freier, Kenneth W. Dobie
  • Notch1 inhibitors for inducing apoptosis
    Publication number: 20030225019
    Abstract: Compounds, compositions and methods are provided for modulating the expression of Notch1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Notch1. Methods of using these compounds for modulation of Notch1 expression and for diagnosis and treatment of disease associated with expression Notch1 are provided.
    Type: Application
    Filed: January 21, 2003
    Publication date: December 4, 2003
    Inventors: Susan M. Freier, Kenneth W. Dobie, Erich Koller